KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Other Operating Expenses (2019 - 2025)

Historic Other Operating Expenses for Castle Biosciences (CSTL) over the last 7 years, with Q3 2025 value amounting to $21.0 million.

  • Castle Biosciences' Other Operating Expenses rose 1733.12% to $21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.8 million, marking a year-over-year increase of 6156.81%. This contributed to the annual value of $71.3 million for FY2024, which is 3206.96% up from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Other Operating Expenses is $21.0 million, which was up 1733.12% from $19.6 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Other Operating Expenses high stood at $44.7 million for Q1 2025, and its period low was -$10.6 million during Q2 2022.
  • For the 5-year period, Castle Biosciences' Other Operating Expenses averaged around $13.7 million, with its median value being $13.4 million (2023).
  • Its Other Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 139734.85% in 2021, then tumbled by 36853.02% in 2022.
  • Over the past 5 years, Castle Biosciences' Other Operating Expenses (Quarter) stood at $5.6 million in 2021, then soared by 104.01% to $11.4 million in 2022, then grew by 28.5% to $14.7 million in 2023, then surged by 39.67% to $20.5 million in 2024, then increased by 2.23% to $21.0 million in 2025.
  • Its Other Operating Expenses stands at $21.0 million for Q3 2025, versus $19.6 million for Q2 2025 and $44.7 million for Q1 2025.